Key Details
Price
$80.50Annual EPS
-$2.17Annual ROE
-18.02%Beta
1.33Events Calendar
Next earnings date:
Feb 27, 2025Recent quarterly earnings:
Nov 12, 2024Recent annual earnings:
Feb 27, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
CAMBRIDGE, Mass., Dec. 19, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company in the clinical stage that aims to develop targeted treatments for confirmed kinase targets in cancer, has announced today that James Porter, Ph.D.
On December 9, 2024, in Cambridge, Massachusetts, Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company in the clinical stage that develops targeted cancer therapies, announced that Grant Bogle has been appointed to its Board of Directors.
The successful completion of all expected milestones for 2024 and faster development schedules support the OnTarget 2026 plan, aiming for the first approved product by 2026. Dr. Alice Shaw, a prominent medical oncologist, has been appointed to the Scientific Advisory Board. The company has a strong cash reserve of $1.2 billion, which includes funds from a larger public offering of $575 million, and this is projected to sustain operations until 2028.
Nuvalent's main drug candidates, NVL-520 and NVL-655, have demonstrated good effectiveness and safety in early trials. They have been granted Breakthrough Therapy and orphan drug status by the FDA, with important Phase 2 results anticipated in 2025 and possible approvals by 2026. The company also raised $500 million through a secondary offering, indicating strong interest from investors and ensuring funding for Phase 3 trials.
On September 18, 2024, Nuvalent, Inc., a biopharmaceutical company based in Cambridge, Massachusetts, announced that it has successfully completed its larger-than-expected public offering of 5,750,000 shares of Class A common stock. This total includes an additional 750,000 shares that the underwriters fully exercised their option to buy. The shares were offered to the public at a price of $100.00 each.
The positive news follows NUVL's announcement of promising results from two experimental treatments for lung cancer.
Nuvalent, Inc. reported encouraging results from the phase 1/2 ALKOVE-1 study, which tested NVL-655 on patients with ALK-mutant non-small cell lung cancer (NSCLC). They also had positive outcomes from the phase 1/2 ARROS-1 study, where zidesamtinib was used for patients with ROS-1 mutant NSCLC. The global market for non-small cell lung cancer is expected to grow to $36.9 billion by 2031, with 3% to 5% of cases being ALK-positive and 1% to 3% being ROS-1 positive.
On September 16, 2024, Nuvalent, Inc., a biopharmaceutical company based in Cambridge, Massachusetts, announced that it has increased its public offering to sell 5,000,000 shares of Class A common stock. The shares are priced at $100.00 each for the public. The company focuses on developing targeted therapies for specific kinase targets in cancer treatment.
During the weekend, Nuvalent, Inc. (NUVL) showcased new information from the Phase 1 dose-escalation stages of the ongoing ARROS-1 Phase 1/2 trial for zidesamtinib and the ALKOVE-1 Phase 1/2 trial for NVL-655 at the European Society for Medical Oncology (ESMO) Congress 2024.
Biotech company Nuvalent shared new information about two experimental cancer drugs over the weekend. Experts believe that both could be the top treatments in their respective categories.
FAQ
- What is the primary business of Nuvalent?
- What is the ticker symbol for Nuvalent?
- Does Nuvalent pay dividends?
- What sector is Nuvalent in?
- What industry is Nuvalent in?
- What country is Nuvalent based in?
- When did Nuvalent go public?
- Is Nuvalent in the S&P 500?
- Is Nuvalent in the NASDAQ 100?
- Is Nuvalent in the Dow Jones?
- When was Nuvalent's last earnings report?
- When does Nuvalent report earnings?
- Should I buy Nuvalent stock now?